Nextech Invest Ltd., a Zurich, Switzerland-based specialist oncology private equity investor, closed its fourth fund, at $64m.
Oncology Fund IV, whose Limited Partners are based in the USA, Europe and Asia, will be invested in companies that develop therapeutics for the treatment of cancer.
The fund has already made investments in Peloton Therapeutics, Kura Oncology (NASDAQ: KURA), and Jounce Therapeutics.
Established in 1998 by Alfred Scheidegger, Nextech Invest focuses on investing in cancer companies. Since its inception, it has raised more than $250m distributed across four funds, three of which are focused uniquely on investing in Oncology.
It is supported by a Scientific Board of eight oncologists chaired by Prof. Dr. David Livingston, Deputy Director of Dana-Farber/Harvard Cancer Center, and including
– Prof. Dr. Karl-Heinz Altmann,
– Prof. Dr. Philip Greenberg,
– Prof. Dr. William Kaelin,
– Dr. Charles Sawyers,
– Prof. Dr. Paul Workman,
– Dr. Kai Wucherpfennig and
– Prof. Dr. Sir Bruce Ponder.